Bio-Rad Upgraded to Buy by Citi; Downgrades for Charles River and Hologic

Tuesday, 1 October 2024, 22:09
Bio-Rad Laboratories saw an upgrade to buy from Citi, while Charles River Laboratories and Hologic received downgrades. This shift comes ahead of the critical Q3 earnings season, highlighting significant movements in the market. Investors should take note of these changes as they could impact stock performance in the upcoming financial reporting period.
Seekingalpha
Bio-Rad Upgraded to Buy by Citi; Downgrades for Charles River and Hologic

Market Movements: Bio-Rad's Upgrade

Citi has upgraded Bio-Rad Laboratories (BIO) to buy, reflecting a positive outlook on its performance amidst evolving market conditions. This upgrade suggests confidence in Bio-Rad's growth potential as we approach the crucial Q3 earnings season.

Downgrades for Hologic and Charles River

  • Citi downgraded Hologic (HOLX) to neutral, indicating concerns about its current market position.
  • Charles River Laboratories (CRL) has been downgraded to sell, reflecting caution ahead of its earnings report.

These adjustments signal a pivotal moment for investors focusing on these key players in the healthcare sector.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe